Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Ohio Urology Group

Neither a doctor nor a teaching hospital

Research payments

$251,285

52 payments

Through program year 2025, Central Ohio Urology Group is reported as receiving $251,285 in research payments, across 52 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $121,993 23
2024 Research $73,846 14
2023 Research $53,421 11
2021 Research $1,511 2
2019 Research $514 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $104,593 12 payments
  2. Dendreon Pharmaceuticals LLC $87,300 15 payments
  3. Sumitomo Pharma America, Inc. $33,412 14 payments
  4. Ironwood Pharmaceuticals, Inc $12,950 4 payments
  5. Ferring Pharmaceuticals AS $11,006 3 payments
  6. AstraZeneca Pharmaceuticals LP $2,024 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. ProvONE Study $51,500 8 payments
  2. Aramon $37,911 6 payments
  3. ProvONE $35,800 7 payments
  4. A 2-stage, Lead-in and Randomized, Phase 2, Open-label study of Darolutamide versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men with Hormone-Nave Prostate Cancer $34,365 4 payments
  5. BAY 1841788, A 2-stage, Lead-in and Randomized, Phase 2, Open-label study of Darolutamide versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men with Hormone-Nave Prostate Cancer $32,317 2 payments
  6. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $17,371 5 payments
  7. C3300-201 $12,950 4 payments
  8. ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States $11,006 3 payments
  9. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $9,541 6 payments
  10. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $5,750 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record